Business Wire

Convert Group Study: COVID-19 Drew More Than 2.7 Billion Visits to Global ePharmacies in 96 Countries in Q1'21


Consumers and patients globally have turned to digital platforms to purchase their prescription (Rx), non-prescription (OTC) medication and parapharmacy products with more than 2.7 billion online visits to leading ePharmacies across 96 countries in Q1’21. This represents an astonishing 43% growth rate compared to Q1’20. The details of this global research have been published online at

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

ePharmacies Visits Growth in Q1 of 2021 Across the World (Graphic: Business Wire)

The study highlights the unique opportunity for Consumer Healthcare Retailers and Manufacturers to address the new habits of consumers and patients purchasing their prescription (Rx) and non-prescription (OTC) medicine and parapharmacy products online. Out of the 96 countries having at least 1 online pharmacy, consumers can order their prescription drugs onlinein 47 countries. The COVID-19 pandemic, wide adoption of electronic prescription,and themodernisation of last mile logistics have worked wonders towards allowing the sale of prescription drugs through eCommerce in the last year, something that was unimaginable 5 years ago in most of the 47 countries. For example, in April 2020 the State Duma of the Russian Federation legalized within days, after years of deliberation, the online sales of prescription and over-the-counter drugs, with the exception of narcotic and psychotropic drugs.

Online Pharmacies are one of the fastest rising eCommerce sectors in the world:

Amazon invested heavily in the industry with the acquisition of PillPack in 2020.

JD Health, a unit of Inc., increased its revenue, jumping to a +76% year-over-year growth to $1.34 billion, in the first six months of 2020.

Alibaba-backed Alibaba Health posted a +74% revenue increase over the March to September 2020 period.

● While brick and mortar pharmacy chains such as CVS & Walgreens in the USA surpass 100 million online visits and Boots averages20 million online visits, pure ecommerce players such as 1mg in India, Consultaremedios in Brazil and Apteka in Russia have been growing extremely fast, with more than 20 million visits per month on average for the last 6 months, disrupting global markets with services such as doctors appointments booking, marketplace capabilities and online consultations.

The research was performed by Convert Group, the leading global ePharmacy Data firm that Consumer Healthcare & FMCG Manufacturers such as Bayer, GSK, J&J, L'Oréal, Nestlé, P&G, Perrigo, Pierre Fabre, Reckitt Benckiser, Roche, Unilever, and others trust for their data-driven strategy and sell-out insights on the eCommerce channel. Traffic data was drawn with permission from Similarweb, the global leading provider of digital market intelligence, for 3.478 Online Pharmacies in 96 Countries across all continents.

Key findings include:

47 in 96 countries allow the online ordering of prescription medicine (Rx)

88 in 96 countries allow the online ordering of non-prescription medicine (OTC). The only countries prohibiting it are Algeria, Cyprus, Greece, Morocco and Turkey.

North America was the region with the highest growth, with online visits increasing by +114%. Online visits increased by +80% in South America and +78% in Northern Africa.

Sweden was the leading country with 18,001 visits to online pharmacies per 1,000 residents, followed by 13,208 visits per 1,000 residents in Bulgaria, 10,418 visits per 1,000 residents in Lithuania, and x 9,739 visits per 1,000 residents in the UK.

Brazil has the most tier1 online pharmacies (pharmacies with more than 5M visits per average month in Q1’21) with 6 total, followed by Russia with 4, and the U.S., UK and India with 3 each.

Panayotis Gezerlis, CEO of Convert Group, commented: "During the first lockdown we saw the majority of patients & consumers across countries adopting online purchase habits from ePharmacies with tremendous speed. Many of the newcomers were also supported by ePrescription legislation being adopted across a number of countries, beside the current global eCommerce hype. In some countries more than 20% of Consumer Healthcare revenues are now originating online. We feel that, with the current growth trends, it is likely that by 2035 more than half of the total sales of Rx, OTC and parapharmacy products will be happening online, in the majority of global markets."

The results of the study are now published on the newly-launched and will be distributed at the 2021 Global ePharmacy Summit on September 22 - 24, 2021, hosted by Convert Group. will be updated monthly to offer the global Consumer Healthcare community insights and data on one of the fastest rising sectors of global eCommerce.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Labrini Bena
Marketing Communications Manager
+30 215 215 0532

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gopher Response to Statement by Playtech, Related Clarifications and Reasons Why Shareholders Should VOTE AGAINST the Consortium Offer3.8.2021 09:09:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Gopher Investments (“Gopher”), a 4.97% shareholder in Playtech plc (“Playtech”), is highly disappointed with the Board of Playtech’s decision not to change its recommendation in relation to the offer from Finalto’s management team backed by a consortium led by Barinboim Group (the “Consortium”). Gopher does not believe the supplementary circular contains a full and fair representation of the interaction between Gopher and Playtech since the previous adjournment of the general meeting and therefore wishes to clarify the following chain of events: Gopher responded promptly to an initial information request from the Board, relating to Gopher’s financing and its high confidence of regulatory approval. The Board sought additional information which was commercially conf

SES Networks Expands Partnership With Orange to Enhance Maritime Services3.8.2021 08:50:00 CEST | Press release

Orange maritime customers will now be able to accelerate their digital transformation with higher-capacity satellite connectivity services provided jointly by SES Networks and Orange. This press release features multimedia. View the full release here: SES Networks Expands Partnership With Orange to Enhance Maritime Services (Photo: Business Wire) With this innovative agreement, Orange will integrate its own global infrastructure with the global network coverage powered by SES Networks’ Skala Global Platform. Together it will enable Orange maritime customers to cost-effectively scale up their bandwidth with seamless, ubiquitous and global services. This will ensure they can implement new technologies onboard that take advantage of IoT and AI, as well as edge and cloud applications. The combination of the Orange secured and digital network infrastructure and SES Networks’ Skala Global Platform -- a next-generation technology platf

Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis3.8.2021 07:03:00 CEST | Press release

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief” or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that, via its newly acquired subsidiary, AdVita Lifescience GmbH, the Company has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”) for RLF-100 (aviptadil), an inhaled formulation in development for the treatment of sarcoidosis. RLF-100 is a synthetic form of vasoactive intestinal peptide. In open label exploratory clinical experience in sarcoidosis patients, RLF-100 has been shown to be well tolerated and safe, and to produce favorable immunoregulatory effects in the lungs that have been associated with symptom relief in a significant proportion of the patients. “Receipt of our third Orphan Drug Designation is another important milestone for the Company, as it underscores the potential strength of our pipeline and the high need for be

Smart Engages P.I. Works for Expanded Network Automation Solution3.8.2021 07:00:00 CEST | Press release

Smart Communications, Inc. (Smart), the wireless unit of the Philippines’ largest, fully integrated telecommunications company PLDT, has partnered with P.I. Works for a comprehensive strategy for its Self-Organizing Network (SON) Solution to automate its multi-vendor, multi-technology networks. A self-organizing network (SON) is an automation technology designed to make the planning, configuration, performance management, coverage and quality optimization and healing of mobile radio access networks efficient, simpler and faster. This automation is expected to significantly improve the performancemanagement and service quality enhancements of the Smart wireless network, which will result in an improved experience for Smart customers across the country. Under its Network Operations Transformation program, Smart started working with P.I. Works in 2018 through another entity, to enable Artificial Intelligence (AI) and Machine Learning (ML) technologies for the automation of various network

Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients2.8.2021 22:05:00 CEST | Press release

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study "Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms,"(1) in Clinical Cancer Research, a journal published by the American Association for Cancer Research. The study details the development of the Personalis Neoantigen Presentation Score (NEOPS™), a novel composite biomarker for predicting response to cancer immunotherapy. Enabled by comprehensive tumor immunogenomic profiling from the Personalis NeXT Platform, NEOPS simultaneously models both neoantigen burden and immune-related resistance mechanisms to better predict immunotherapy response in a cohort of late-stage melanoma patients. In this study, NEOPS was more strongly predictive of therapy response than other standard single analyte and investigational biomarkers tested, including tumor mutational b

The Consortium Welcomes Playtech’s Confirmed Recommendation for Its Binding Agreement to Acquire Finalto and Urges Investors to Vote in Favour at the Playtech Adjourned General Meeting on 18 August 20212.8.2021 19:41:00 CEST | Press release

Finalto S.P.V. Ltd, the consortium led by Barinboim Group and backed by Leumi Partners Limited and Menora Mivtachim Group, together with key members of the Finalto Business' management team (together the "Consortium"), welcomes the announcement by Playtech plc (“Playtech”) confirming its recommendation that shareholders vote in favour of the Consortium’s binding agreement for Finalto Group (“Finalto) (the “Binding Agreement”). Playtech announced today that following its engagement with Gopher Investments (“Gopher”) over the past three weeks, it has not received responses from Gopher to a number of its questions and therefore “Playtech has not yet been able to achieve the necessary clarity on Gopher's ultimate ownership and funding structure, source of funds or ability to obtain the required regulatory clearances”. Shareholders should ask why Gopher continues to hide and should also be suspicious of Gopher’s credibility, particularly given that disclosure is crucial when buying a highly

Lenovo Climbs 65 Places to Record #159 On ‘FORTUNE Global 500’ List2.8.2021 17:09:00 CEST | Press release

After achieving historical 2021 fiscal year results, Lenovo has been ranked #159 on FORTUNE’s annual Global 500 List and in the top 20 (#15) of all Technology sector companies cited in the List. Lenovo jumped 65 spots this year to an all-time high ranking due to its record financial results, which saw the Group surge past the US$60 billion revenue mark, and adding more than US$10 billion from the previous fiscal year as all core businesses grew. The Fortune Global 500 is the annual ranking of the largest 500 corporations in the world as measured by total revenue. Together, companies on The Global 500 generated US$31.7 trillion in revenue and US$1.6 trillion in profits in 2020, employ 69.7 million people worldwide and are represented by 31 countries. Lenovo’s updated ranking reflects the company’s clear strategy, product innovation, operational excellence, and global/local footprint within the past year. These results reinforced the company’s resilience and ability to achieve balanced,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom